The reduction in price target by a major financial institution like JP Morgan, especially when maintained by a known analyst such as Anupam Rama, can lead to a negative short-term impact on the stock price of RAPT Therapeutics. Investors often view such adjustments as a signal of expected underperformance relative to the market or sector, which can lead to decreased investor confidence and selling pressure.